Get the Stockscreener App
3.495
2.77%
-0.115
Alvotech stock is traded at $3.495, with a volume of 420.51K.
It is down -2.77% in the last 24 hours and down -0.85% over the past month.
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.
See More
Previous Close:
$3.61
Open:
$3.65
24h Volume:
420.51K
Relative Volume:
0.64
Market Cap:
$1.18B
Revenue:
$563.46M
Net Income/Loss:
$27.92M
P/E Ratio:
36.26
EPS:
0.0964
Net Cash Flow:
$-146.33M
1W Performance:
-5.65%
1M Performance:
-0.85%
6M Performance:
-23.36%
1Y Performance:
-61.81%
1-Day Range:
$3.48
$3.72
1-Week Range:
$3.51
$3.95
52-Week Range:
$2.94
$9.94
Alvotech Stock (ALVO) Company Profile
Compare ALVO vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALVO
Alvotech
|
3.495 | 1.25B | 563.46M | 27.92M | -146.33M | 0.0964 |
TAK
Takeda Pharmaceutical Co Adr
|
16.91 | 50.65B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.725 | 41.09B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.12 | 39.45B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
75.28 | 30.13B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
549.23 | 23.00B | 3.17B | 1.29B | 1.01B | 27.09 |
Alvotech Stock (ALVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-25 | Initiated | Barclays | Underweight |
| Nov-04-25 | Downgrade | Deutsche Bank | Buy → Hold |
| Oct-14-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-23-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-14-25 | Initiated | UBS | Buy |
| Jan-29-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Upgrade | Citigroup | Sell → Neutral |
| Sep-21-23 | Initiated | Barclays | Equal Weight |
| Sep-07-22 | Initiated | Morgan Stanley | Equal-Weight |
| Sep-06-22 | Downgrade | Citigroup | Buy → Sell |
| Jul-26-22 | Initiated | Citigroup | Buy |
View All
Alvotech Stock (ALVO) Latest News
Alvotech’s US$240 Million Capital Boost Might Change The Case For Investing In Alvotech (ALVO) - Yahoo Finance
Alvotech Secures Term Loan Facility of $75MM from GoldenTree Asset Management - ABF Journal
Alvotech announced that it has received $175 million in funding - marketscreener.com
Biotech firm Alvotech expands capital access with $75M term loan facility - MSN
Alvotech (NASDAQ: ALVO) adds $75M term loan, lifting new capital access to $240M - Stock Titan
Alvotech Secures Additional $75 Million Term Loan Facility Led By GoldenTree Asset Management - marketscreener.com
Alvotech Secures Additional $75 Million Term Loan Facility Led by GoldenTree Asset Management Following Recent Equity Raise - Quiver Quantitative
Alvotech adds $75M debt after $165M equity raise - Stock Titan
Form 13D/A Alvotech For: 30 June By Investing.com - Investing.com Australia
Celtic Lux (ALVO) boosts Alvotech holding with $38M PIPE and $40M loan - Stock Titan
Why is Alvotech stock rallying today? By Investing.com - Investing.com Nigeria
Alvotech Warrant 2022-open end on Financial Disclosures & SEC Filings - TradingView
Alvotech Announces $152 Million Public Offering and Concurrent Private Placement - Global Legal Chronicle
Alvotech Swedish Depository Receipt Repr 1 Sh Actuals & Estimates (TURQUOISE:ALVOS) - TradingView
Price to book forward of Alvotech – NASDAQ:ALVOW - TradingView
Number of shareholders of Alvotech – NASDAQ:ALVOW - TradingView
Enterprise value to revenue forward of Alvotech – NASDAQ:ALVOW - TradingView
Alvotech Stock 12‑Month Price Target Cut to $6.56, Implies 78% Upside - TradingView
Alvotech Swedish Depository Receipt Repr 1 Sh Actuals & Estimates (DUS:Z450) - TradingView
ALVOS Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to revenue forward of Alvotech – BOATS:ALVOW - TradingView
Alvotech Swedish Depository Receipt Repr 1 Sh Actuals & Estimates (FWB:Z450) - TradingView
Enterprise value to EBIT forward of Alvotech – BOATS:ALVOW - TradingView
Enterprise value to EBITDA forward of Alvotech – BOATS:ALVOW - TradingView
What Does Alvotech's Executive Team Change Signify - Kavout | AI
ALVO Stock Price Prediction 2025-2026 | Alvotech Forecast - 24/7 Wall St.
Z450 Forecast — Price Target — Prediction for 2027 - TradingView
Alvotech initiates $125M fundraising via public and private offering for biosimilar growth - MSN
Alvotech Swedish Depository Receipt Repr 1 Sh Actuals & Estimates (OMXSTO:ALVO_SDB) - TradingView
ALVO_SDB Forecast — Price Target — Prediction for 2027 - TradingView
Alvotech Actuals & Estimates (NASDAQ:ALVO) - TradingView
Alvotech (ALVO) Stock Could Be 71.7% Undervalued After Its $165 Million Capital Raise - simplywall.st
Transactions of Managers and Closely Associated Persons - The Manila Times
Alvotech Announces CSSF Filing on Celtic Lux Holdings' Acquisition of 10.1 Million Shares at $3.75 Each - Moomoo
Alvotech Announces CSSF Filing on Celtic Lux Holdings’ Acquisition of 10.1 Million Shares at $3.75 Each - Quiver Quantitative
Alvotech manager filing shows 10.1M shares bought at $3.75 - Stock Titan
J&J Units Target Alvotech Simponi Biosimilars in Patent Suit (1) - Bloomberg Law News
Alvotech cashes up, SynAct narrowly misses – the Nordic Pulse | 2026:25 - Biostock
Alvotech (ALVO) Jefferies Global Healthcare Conference 2026 Summary - Quartr
Alvotech (ALVO) UBS Virtual Generics and Biosimilars Day Summary - Quartr
Alvotech (ALVO) Bank of America Global Healthcare Conference 2026 Summary - Quartr
Alvotech SA (ALVOW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Alvotech (ALVO): 10 Penny Stocks With Explosive Growth Potential - Yahoo Finance
Alvotech Raises $165 Million Through Share Offering and Concurrent Private Placement - The Globe and Mail
Janssen Commences BPCIA Litigation Against Alvotech for Biosimilar Golimumab - Pearce IP
Alvotech (NASDAQ: ALVO) secures $165M through share sale and private placement - Stock Titan
Alvotech completes offering and raises ~$165 million - The Pharma Letter
symbol__ Stock Quote Price and Forecast - CNN
Alvotech closes $98M public offering at $3.75 per share - Investing.com UK
Alvotech closes $98M public offering at $3.75 per share By Investing.com - Investing.com South Africa
Alvotech Raises $165 Million Through A Two-Step Share Sale - Finimize
Alvotech Stock (ALVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.02%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):